Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

First Posted Date
2004-05-19
Last Posted Date
2013-10-16
Lead Sponsor
Children's Hospital of Philadelphia
Target Recruit Count
43
Registration Number
NCT00002961
Locations
🇺🇸

Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States

🇺🇸

Nemours Children's Clinic, Jacksonville, Florida, United States

🇺🇸

Children's Mercy Hospital, Kansas City, Missouri, United States

and more 15 locations

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

First Posted Date
2004-05-03
Last Posted Date
2017-04-04
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
5
Registration Number
NCT00005988
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2004-04-27
Last Posted Date
2014-03-07
Lead Sponsor
University of Chicago
Target Recruit Count
16
Registration Number
NCT00003950
Locations
🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

and more 7 locations

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

First Posted Date
2004-04-26
Last Posted Date
2011-11-30
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00002456
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

First Posted Date
2004-04-15
Last Posted Date
2020-02-06
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
40
Registration Number
NCT00003954
Locations
🇺🇸

University of Colorado, Denver, Colorado, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

First Posted Date
2004-04-08
Last Posted Date
2014-12-04
Lead Sponsor
Mesoblast International Sàrl
Registration Number
NCT00081055
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

First Posted Date
2004-03-26
Last Posted Date
2013-02-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
3
Registration Number
NCT00002759
Locations
🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath